Unrelated umbilical cord blood (UCB) is a new source of hematopoietic stem cell (HSC) for allogeneic transplantation. The optimal conditioning for UCB transplant has not been defined. Intensive immunosuppression is frequently employed because of the higher risk of graft failure. Fludarabine monophosphate is shown to be an effective agent for facilitating allogeneic HSC engraftment. We have recently encountered three children who were not ideal candidates for 'conventional' conditioning protocols. TBI followed by fludarabine and melphalan were used for transplant preparation. The UCB units were one HLA-antigen (n ‫؍‬ 1) and two HLA-antigen mismatched with the recipients. All three patients engrafted successfully. There was mild extramedullary toxicity. Two patients are alive with complete chimerism 8 and 20 months after transplant. A fludarabine-based protocol may be considered for selected cases of UCB transplants. Keywords: umbilical cord blood transplant; fludarabine; total body irradiation; melphalan; unrelated donor Umbilical cord blood (UCB) from unrelated donors has emerged as a potential source of hematopoietic stem cells (HSC) for patients in need of an allogeneic transplant.
Umbilical cord blood (UCB) from unrelated donors has emerged as a potential source of hematopoietic stem cells (HSC) for patients in need of an allogeneic transplant. [1] [2] [3] The best pretransplant conditioning regimen has not been established. A higher incidence of graft failure has been reported from unrelated UCB transplants, probably as the result of smaller total cell dose available from individual cord blood units and in most cases some degree of HLA disparity between the donor and the recipients.
1,2 Total body irradiation (TBI) in high doses and anti-T cell antibody are frequently included in the preparative protocol for immunosuppression.
Fludarabine-based protocols have been used successfully to facilitate engraftment in allogeneic hematopoietic stem cell transplantation. [4] [5] [6] [7] [8] We recently encountered three patients who were poor candidates for the conventional pretransplant conditioning. They received a preparative regimen that included TBI, fludarabine and melphalan. The regimen was well tolerated and all patients engrafted successfully.
Case reports

Case 1
A 15-year-old boy was diagnosed with stage IV T cell nonHodgkin's lymphoma in July 1992. He achieved a complete response but developed an isolated meningeal relapse at the end of the second year of chemotherapy. He received further systemic chemotherapy and craniospinal irradiation (24 Gy cranium and 15 Gy spine). He developed hemorrhagic cystitis while on retrieval therapy. Three months after completion of treatment, he was found to have thrombocytopenia. Bone marrow examination revealed features of myelodysplasia, with 0.6% blasts and 10% ring sideroblasts. Cytogenetic analysis showed complex abnormalities including hypodiploid clones, loss of Y chromosome and monosomy 5, 7 and 8. Conditioning before unrelated UCB transplant included TBI 1.7 Gy twice daily for five doses (on days Ϫ8 to Ϫ6); fludarabine monophosphate 30 mg/m 2 /day i.v. on 4 consecutive days (days Ϫ5 to Ϫ2); and melphalan 140 mg/m 2 i.v. on day Ϫ1. The post-transplant course was uncomplicated except for 2 days of mild dysphagia and fever for 24 h. He was discharged 24 days after transplant after recovery of his blood counts ( Table  1) . GVHD of the skin (grade II) developed but responded to systemic steroid therapy. No chronic GVHD was found. The patient had asymptomatic CMV antigenemia that resolved with ganciclovir. Complete engraftment was documented by RFLP studies on bone marrow examination at 1, 3, 6 and 12 months post-transplant. The patient remains well 20 months later. 
Case 2
A 16-month-old boy was diagnosed with AMMoL in January 1997. He was treated with 6 months of chemotherapy but developed an isolated meningeal relapse at the end of treatment. He received intrathecal and intraventricular chemotherapy and systemic reinduction with high-dose Ara-C and fludarabine (35 mg/m 2 /day i.v. ϫ 2). In December 1997 he was given cranial irradiation (1.8 Gy daily for seven fractions). This was followed by preparation for UCB transplant 10 days later. TBI was delivered at 2 Gy per day for 4 consecutive days (days Ϫ9 to Ϫ6), followed by fludarabine and melphalan as in case 1. He developed grade I diarrhea but no oral mucositis. Alpha hemolytic streptococcal septicemia developed which was accompanied by transient elevation of transaminases. These complications resolved quickly as the granulocyte counts recovered. He was discharged on day 21. There was no evidence of acute GVHD. He had no other complications. Bone marrow examinations at 1 and 3 months after transplant documented complete engraftment by RFLP analysis. The patient remains well with normal blood counts 8 months later.
Case 3
An 11.5-year-old boy was diagnosed with AMMoL in December 1996. He underwent autologous BMT during first CR in May 1997. The preparative regimen included BU 16 mg/kg and CY 200 mg/kg. The post-BMT course was complicated by serious JK virus-associated hemorrhagic cystitis. His leukemia relapsed in November 1997. He achieved a second CR with reinduction chemotherapy that included fludarabine, Ara-C and idarubicin. As there was no matched related donor available, the patient underwent an unrelated mismatched UCB transplantation in March 1998. The conditioning regimen was the same as for case 2 but he also received anti-thymocyte globulin 15 mg/kg/day i.v. for 6 consecutive days (days Ϫ6 to Ϫ1) and methylprednisolone 1 mg/kg/day i.v. on 4 consecutive days (days Ϫ4 to Ϫ1). No extramedullary toxicity other than a transient skin rash was encountered. The patient developed grade II GVHD of the skin and gut, which responded to systemic steroids. The patient also had multiple infections including bacteremia (coagulase negative staphylococci), CMV and HSV reactivation, Pseudomonas pneumonia and Candida glabrata colonization. Granulocyte recovery occurred on day ϩ42 but he never became platelet transfusion-independent. However, bone marrow examination on day 42 and 90 showed plenty of megakaryocytes.
Engraftment was confirmed by RFLP analysis. He developed lobar pneumonia and died of respiratory failure on day ϩ96.
Discussion
Our experience shows that engraftment of mismatched, unrelated UCB can be achieved with a preparative regimen consisting of fludarabine, melphalan and total body irradiation. Fludarabine is a potent immunosuppressive agent and has been used successfully in allogeneic HSC transplantation. Terenzi et al 4 has demonstrated that fludarabine can replace cyclophosphamide in pretransplant conditioning. Successful engraftment of allogeneic progenitor cells was reported with a combination of fludarabine and other chemotherapy at nonmyeloablative doses. 5 Chimerism can be established with either matched sibling or unrelated marrow donor grafts. [5] [6] [7] [8] Slavin et al 7 reported conditioning of matched sibling blood cell transplants with fludarabine, low-dose busulfan and anti-T-lymphocyte globulin. Stable mixed or complete chimerism was shown in all patients. The engraftment of allogeneic hematopoietic stem cells is affected by several factors including the cell dose, intensity of immunosuppression and degree of genetic disparity. 9 As most unrelated UCB transplants involve HLA disparity between donor and recipient and a low number of nucleated cells available in each unit, we included total body irradiation in the preparative regimen. A total dose of 8 and 8.5 Gy was chosen because this was shown to be an effective immunosuppressant in transplantation of patients with aplastic anemia using unrelated and mismatched family donors. 10, 11 Radiation given before fludarabine was more efficacious in eradicating T-suppressor cells than when administered the other way around. 4 Whether this regimen is sufficient for engraftment of more than two HLA-antigen-mismatched grafts requires further study.
Neurotoxicity is the major complication of fludarabine treatment and appears to be dose-dependent. Previous reports have shown that fludarabine-based preparative regimens are well tolerated. Giralt et al 5 transplanted patients who were not eligible for conventional myeloablative conditioning because of advanced age and/or poor performance status. Only one of 15 patients died of transplant-related mortality. In patients in better physical condition, Slavin et al 7 reported no grade 3 or 4 toxicity in 26 patients transplanted. Despite the inclusion of total body irradiation in the regimen, our patients experienced only transient and mild extramedullary toxicity. This included the baby (case 2) who had just completed 12.6 Gy of cranial irradiation 2 weeks earlier. It should be pointed out that all three patients had good performance status with minimal active disease at the time of transplant, so the spectrum of side-effects of this regimen requires further observation, especially in patients with more advanced disease. The most common causes of treatment failure of unrelated UCB transplants were infections and interstitial pneumonitis. [1] [2] [3] In patient 3, delayed platelet recovery was probably due to the small dose of donor cells, CMV infection and GVHD. Two of the three patients were engrafted without receiving antithymocyte globulin and methylprednisolone, so the role of these agents in conditioning is not clear. If the regimen can be validated in a greater number of UCB transplants, reduction of the TBI dose and omission of anti-thymocyte globulin and high-dose steroid will provide a useful alternative for patients at high risk of infections and interstitial pneumonitis.
